Sugi Predict

Sugi Predict / Compounds / SCHEMBL2249647

SCHEMBL2249647

SCHEMBL2249647

COC(=O)c1cc(Cl)ncc1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.45
▸ LMNA P02545 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ ABL1 P00519 1/20 0.40
▸ GAA P10253 2/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ TTBK1 Q5TCY1 1/20 0.38
▸ TTBK2 Q6IQ55 1/20 0.38
▸ TSHR P16473 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ ATR Q13535 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30031524 1.00 KDM4E (0.45) KDM4ELMNAMAPK1ABL1GAA
SCHEMBL30824189 0.86 KDM4E (0.42) KDM4ELMNAMAPK1ABL1GAA
SCHEMBL27170871 0.86 KDM4E (0.42) KDM4ELMNAMAPK1ABL1GAA
SCHEMBL977733 0.84 KDM4E (0.49) KDM4ELMNAMAPK1ABL1GAA
SCHEMBL29416286 0.84 KDM4E (0.49) KDM4ELMNAMAPK1ABL1GAA
SCHEMBL236107 0.82 KDM4E (0.47) KDM4ELMNAMAPK1ABL1GAA
SCHEMBL30217866 0.82 KDM4E (0.47) KDM4ELMNAMAPK1ABL1GAA
SCHEMBL19813985 0.82 L3MBTL1 (0.41) KDM4EMAPK1GAAL3MBTL1TTBK1
SCHEMBL15770624 0.82 CYP4F2 (0.46) KDM4ELMNAMAPK1SMN1; SMN2NPC1
SCHEMBL15712602 0.82 ATR (0.38) LMNAGAANPC1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12623919-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2026-05-12 — — US disclosed
EP-4724441-A1 ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF Revir Therapeutics, Inc. (US) 2026-04-15 — — EP disclosed
EP-4713096-A1 CDK INHIBITOR COMPOUNDS Aleksia Therapeutics, Inc. (US) 2026-03-25 — — EP disclosed
US-20260049074-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. (US) 2026-02-19 — — US disclosed
US-12552772-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2026-02-17 — — US disclosed
EP-4306529-B1 FGFR INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS INC (US) 2026-01-21 — — EP disclosed
US-12522605-B2 FGFR inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2026-01-13 — — US disclosed
US-12509454-B2 Thiadiazolyl derivatives IDEAYA BIOSCIENCES, INC. (US) 2025-12-30 — — US disclosed
WO-2025262433-A1 N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2025-12-26 — — WO disclosed
US-12473280-B2 Substituted tricyclic compound as PRMT5 inhibitor and use thereof NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2025-11-18 — — US disclosed
EP-2350010-B1 ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2014-03-26 — — EP disclosed
EP-2350010-B1 ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2014-03-26 — — EP disclosed
US-8592457-B2 Isonicotinamide orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2013-11-26 — — US disclosed
CN-102272103-A Isonicotinamide orexin receptor antagonists — 2011-12-07 — — CN disclosed
US-20110201591-A1 ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2011-08-18 — — US disclosed
US-20110201591-A1 ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2011-08-18 — — US disclosed
US-20110201591-A1 ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2011-08-18 — — US disclosed
EP-2350010-A1 ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2011-08-03 — — EP disclosed
WO-2010051236-A1 ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2010-05-06 — — WO disclosed
WO-2010051236-A1 ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2010-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049074-A1 THIADIAZOLYL DERIVATIVES POLH, POLM, POLD1 KDM4E 3719/4885LMNA 1109/4885MAPK1 4035/4885
US-12473280-B2 Substituted tricyclic compound as PRMT5 inhibitor and use thereof PRMT5, PRMT1, PRMT8 KDM4E 71/4885LMNA 2398/4885MAPK1 821/4885
US-12552772-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 KDM4E 516/4885LMNA 1915/4885MAPK1 899/4885
US-20110201591-A1 ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NTSR2 KDM4E 3758/4885LMNA 3546/4885MAPK1 3104/4885
US-12623919-B2 Organic electroluminescent materials and devices LBR, OXSR1, ESRRA KDM4E 1753/4885LMNA 1660/4885MAPK1 2588/4885
US-12509454-B2 Thiadiazolyl derivatives POLD1, POLQ, DNA2 KDM4E 3903/4885LMNA 2322/4885MAPK1 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.